3.9 Review

Regulation of Stem Cell Pluripotency and Neural Differentiation by Lysophospholipids

Journal

NEUROSIGNALS
Volume 17, Issue 4, Pages 242-254

Publisher

KARGER
DOI: 10.1159/000231891

Keywords

Ceramide; Lysophosphatidic acid; Sphingosine-1-phosphate; Lysophospholipid; Stem cells, induced pluripotent; Progenitor cells; G-protein-coupled receptors; Signalling pathways; Neural differentiation

Funding

  1. National Health and Medical Research Council of Australia [454723, 508097]
  2. Fay Fuller Foundation and Friedreich Ataxia Research Association

Ask authors/readers for more resources

Lysophospholipids are bioactive signalling molecules able to act through the binding of their specific G-protein-coupled receptors to exert pleiotropic effects on a wide range of cells. The most widely studied signalling lysophospholipids are lysophosphatidic acid (LPA) and sphingosine-1-phosphate (S1P). LPA and S1P have been identified to have widespread developmental, physiological and pathological actions in the central nervous system and more recently have been shown to induce biological effects on various stem cell types. This review aims to summarise the current knowledge on LPA and S1P regulation of embryonic and neural stem cell biology. Copyright (C) 2009 S. Karger AG, Basel

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

3.9
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Oncology

Desmoglein-2 expression is an independent predictor of poor prognosis patients with multiple myeloma

Lisa M. Ebert, Kate Vandyke, M. Zahied Johan, Mark DeNichilo, Lih Y. Tan, Kay K. Myo Min, Benjamin M. Weimann, Brenton W. Ebert, Stuart M. Pitson, Andrew C. W. Zannettino, Craig T. Wallington-Beddoe, Claudine S. Bonder

Summary: Desmoglein-2 (DSG2) is found to be overexpressed in approximately 20% of bone marrow biopsies from newly diagnosed multiple myeloma patients, and it is strongly predictive of poor clinical outcome, independent of genetic subtype or routinely measured biomarkers of MM activity. This cell surface protein may serve as a potential biomarker that can be quickly detected by flow cytometry to predict disease trajectory at the time of diagnosis.

MOLECULAR ONCOLOGY (2022)

Article Biochemistry & Molecular Biology

Targeting human CALR-mutated MPN progenitors with a neoepitope-directed monoclonal antibody

Denis Tvorogov, Chloe A. L. Thompson-Peach, Johannes Fosselteder, Mara Dottore, Frank Stomski, Suraiya A. Onnesha, Kelly Lim, Paul A. B. Moretti, Stuart M. Pitson, David M. Ross, Andreas Reinisch, Daniel Thomas, Angel F. Lopez

Summary: Researchers have developed a specific antibody, 4D7, that can selectively target common CALR mutations, inhibiting the proliferation and megakaryocyte differentiation of mutant CALR myelofibrosis progenitors and providing a novel therapeutic approach.

EMBO REPORTS (2022)

Editorial Material Genetics & Heredity

Genetics of reticular pseudodrusen in age-related macular degeneration

Samaneh Farashi, Zhichao Wu, Carla J. Abbott, Alice Pebay, Erica L. Fletcher, Robyn H. Guymer, Melanie Bahlo, Brendan R. E. Ansell

Summary: Reticular pseudodrusen (RPD) is a distinct phenotype associated with late-stage age-related macular degeneration (AMD), characterized by subretinal deposits. The genetic risk associations of RPD overlap with six established AMD-risk regions. Identifying the specific underlying genetic causes of RPD through adequate imaging methods can enhance our understanding of RPD pathophysiology.

TRENDS IN GENETICS (2022)

Article Multidisciplinary Sciences

The sphingosine 1-phosphate receptor 2/4 antagonist JTE-013 elicits off-target effects on sphingolipid metabolism

Melissa R. Pitman, Alexander C. Lewis, Lorena T. Davies, Paul A. B. Moretti, Dovile Anderson, Darren J. Creek, Jason A. Powell, Stuart M. Pitson

Summary: The study found that JTE-013 has broad off-target effects on sphingolipid metabolism, increasing cellular levels of ceramides, dihydroceramides, sphingosine, and dihydrosphingosine. Additionally, the study revealed that JTE-013 inhibits the activity of several sphingolipid metabolic enzymes.

SCIENTIFIC REPORTS (2022)

Article Oncology

Resensitising proteasome inhibitor-resistant myeloma with sphingosine kinase 2 inhibition

Melissa K. Bennett, Manjun Li, Melinda N. Tea, Melissa R. Pitman, John Toubia, Paul P-S Wang, Dovile Anderson, Darren J. Creek, Robert Z. Orlowski, Briony L. Gliddon, Jason A. Powell, Craig T. Wallington-Beddoe, Stuart M. Pitson

Summary: The introduction of the proteasome inhibitor bortezomib has improved patient survival in myeloma, but acquired resistance remains a challenge. Researchers have found that inhibiting sphingolipid metabolism can resensitize bortezomib-resistant myeloma, and this approach also works with other proteasome inhibitors like carfilzomib.

NEOPLASIA (2022)

Article Oncology

Sphingosine Kinase-1 Is Overexpressed and Correlates with Hypoxia in Osteosarcoma: Relationship with Clinicopathological Parameters

Anne Gomez-Brouchet, Claire Illac, Adeline Ledoux, Pierre-Yves Fortin, Sandra de Barros, Clementine Vabre, Fabien Despas, Sophie Peries, Christelle Casaroli, Corinne Bouvier, Sebastien Aubert, Gonzague de Pinieux, Frederique Larousserie, Louise Galmiche, Franck Talmont, Stuart Pitson, Marie-Lise Maddelein, Olivier Cuvillier

Summary: The SphK1/S1P signaling pathway is involved in the regulation of HIF-1 alpha expression in osteosarcoma under hypoxia. Inhibiting SphK1 and S1P(1) receptor may be a potential treatment target for osteosarcoma patients. Overexpression of SphK1 and S1P(1) is related to hypoxia marker GLUT-1 in osteosarcoma.

CANCERS (2022)

Article Hematology

Ceramide-induced integrated stress response overcomes Bcl-2 inhibitor resistance in acute myeloid leukemia

Alexander C. Lewis, Victoria S. Pope, Melinda N. Tea, Manjun Li, Gus O. Nwosu, Thao M. Nguyen, Craig T. Wallington-Beddoe, Paul A. B. Moretti, Dovile Anderson, Darren J. Creek, Maurizio Costabile, Saira R. Ali, Chloe A. L. Thompson-Peach, B. Kate Dredge, Andrew G. Bert, Gregory J. Goodall, Paul G. Ekert, Anna L. Brown, Richard D'Andrea, Nirmal Robinson, Melissa R. Pitman, Daniel Thomas, David M. Ross, Briony L. Gliddon, Jason A. Powell, Stuart M. Pitson

Summary: In this study, the accumulation of ceramide in AML cells induced an apoptotic integrated stress response through the activation of transcription factor ATF4. This response led to the degradation of the prosurvival protein Mcl-1, resulting in cell death. Combination treatment with the Bcl-2 inhibitor venetoclax synergistically killed AML cells and reduced leukemic stem cells.

BLOOD (2022)

Article Multidisciplinary Sciences

Germline mutations in mitochondrial complex I reveal genetic and targetable vulnerability in IDH1-mutant acute myeloid leukaemia

Mahmoud A. Bassal, Saumya E. Samaraweera, Kelly Lim, Brooks A. Bernard, Sheree Bailey, Satinder Kaur, Paul Leo, John Toubia, Chloe Thompson-Peach, Tran Nguyen, Kyaw Ze Ya Maung, Debora A. Casolari, Diana G. Iarossi, Ilaria S. Pagani, Jason Powell, Stuart Pitson, Siria Natera, Ute Roessner, Ian D. Lewis, Anna L. Brown, Daniel G. Tenen, Nirmal Robinson, David M. Ross, Ravindra Majeti, Thomas J. Gonda, Daniel Thomas, Richard J. D'Andrea

Summary: This study reveals the mutual exclusivity between germline mutations in mitochondrial complex I and somatic mutations in the metabolic enzyme IDH1 in patients with acute myeloid leukemia (AML), and finds that IDH1 mutant cells have increased sensitivity to complex I inhibitors.

NATURE COMMUNICATIONS (2022)

Article Immunology

Characterising Distinct Migratory Profiles of Infiltrating T-Cell Subsets in Human Glioblastoma

Paris M. M. Kollis, Lisa M. M. Ebert, John Toubia, Cameron R. R. Bastow, Rebecca J. J. Ormsby, Santosh I. I. Poonnoose, Sakthi Lenin, Melinda N. N. Tea, Stuart M. M. Pitson, Guillermo A. A. Gomez, Michael P. P. Brown, Tessa Gargett

Summary: This study characterized the chemokine receptor and integrin expression profiles of endogenous glioblastoma-infiltrating T cells and identified potential homing receptor-ligand pairs that could enhance the tumour-homing properties of future T-cell immunotherapies for glioblastoma.

FRONTIERS IN IMMUNOLOGY (2022)

Review Ophthalmology

Human pluripotent stem cells for the modelling of retinal pigment epithelium homeostasis and disease: A review

Jenna C. Hall, Daniel Paull, Alice Pebay, Grace E. Lidgerwood

Summary: Human pluripotent stem cells are powerful tools for studying and modeling retinal diseases, including both monogenic and complex conditions.

CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY (2022)

Article Biochemistry & Molecular Biology

Slit-Robo signalling establishes a Sphingosine-1-phosphate gradient to polarise fin mesenchyme

Harsha Mahabaleshwar, P. Asharani, Tricia Yi Loo, Shze Yung Koh, Melissa R. Pitman, Samuel Kwok, Jiajia Ma, Bo Hu, Fang Lin, Xue Li Lok, Stuart M. Pitson, Timothy E. Saunders, Tom J. Carney

Summary: Mesenchymal cell immigration into growing fins and limb buds drives distal outgrowth, with tensile forces between these cells essential for fin and limb morphogenesis. Morphogens derived from the apical fin domain regulate cell polarity, migration, division, and adhesion of limb mesenchyme cells. The mutant stomp in zebrafish displays defects in fin morphogenesis, including blister formation and loss of orientation and adhesion of immigrating fin mesenchyme cells. The gene encoding Slit3, an axon guidance ligand, is found to be mutated in stomp. Slit ligands derived from immigrating mesenchyme act via Robo receptors at the apical ectodermal ridge (AER) to promote the release of sphingosine-1-phosphate (S1P), which then diffuses back to the mesenchyme to regulate their polarization, orientation, positioning, and adhesion to the interstitial matrix of the fin fold.

EMBO REPORTS (2022)

Article Multidisciplinary Sciences

Transcriptomic and proteomic retinal pigment epithelium signatures of age-related macular degeneration

Anne Senabouth, Maciej Daniszewski, Grace E. Lidgerwood, Helena H. Liang, Damian Hernandez, Mehdi Mirzaei, Stacey N. Keenan, Ran Zhang, Xikun Han, Drew Neavin, Louise Rooney, Maria Isabel G. Lopez Sanchez, Lerna Gulluyan, Joao A. Paulo, Linda Clarke, Lisa S. Kearns, Vikkitharan Gnanasambandapillai, Chia-Ling Chan, Uyen Nguyen, Angela M. Steinmann, Rachael A. McCloy, Nona Farbehi, Vivek K. Gupta, David A. Mackey, Guy Bylsma, Nitin Verma, Stuart MacGregor, Matthew J. Watt, Robyn H. Guymer, Joseph E. Powell, Alex W. Hewitt, Alice Pebay

Summary: Age-related macular degeneration (AMD) is a leading cause of vision loss, and there is currently no approved treatment for AMD with geographic atrophy. This study used patient induced pluripotent stem cell-derived retinal pigment epithelium to investigate disease mechanisms and identified differences in retinal pigment epithelium homeostasis associated with geographic atrophy.

NATURE COMMUNICATIONS (2022)

Article Oncology

GD2-targeting CAR-T cells enhanced by transgenic IL-15 expression are an effective and clinically feasible therapy for glioblastoma

Tessa Gargett, Lisa M. Ebert, Nga T. H. Truong, Paris M. Kollis, Kristyna Sedivakova, Wenbo Yu, Erica C. F. Yeo, Nicole L. Wittwer, Briony L. Gliddon, Melinda N. Tea, Rebecca Ormsby, Santosh Poonnoose, Jake Nowicki, Orazio Vittorio, David S. Ziegler, Stuart M. Pitson, Michael P. Brown

Summary: Targeting the tumor-associated antigen GD2 using CAR-T-cell therapy has shown promising results in controlling tumor growth in primary glioblastoma. Highly functional GD2-specific CAR-T cells can be produced using an approved clinical manufacturing process. The use of markers identified in the study has further improved tumor control rates.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

Article Cell Biology

Lysosomal alterations and decreased electrophysiological activity in CLN3 disease patient-derived cortical neurons

Sueanne Chear, Sharn Perry, Richard Wilson, Aidan Bindoff, Jana Talbot, Tyson L. Ware, Alexandra Grubman, James C. Vickers, Alice Pebay, Jonathan B. Ruddle, Anna E. King, Alex W. Hewitt, Anthony L. Cook

Summary: CLN3 disease is a fatal neurodegenerative disorder caused by mutations in the CLN3 gene. We corrected the mutation in human induced pluripotent stem cells (iPSCs) using CRISPR/Cas9 technology and observed disease-related changes in protein synthesis, trafficking and degradation, and neuronal activity.

DISEASE MODELS & MECHANISMS (2022)

Meeting Abstract Oncology

Dysregulation of 14-3-3 Signaling Adapters in Lung Adenocarcinoma, New Insights Into the Impact on Cancer Cell Biology

R. Hamon, X. Jiang, J. Toubia, C. Coolen, A. Lopez, P. N. Reynolds, S. M. Pitson, J. Woodcock

JOURNAL OF THORACIC ONCOLOGY (2022)

No Data Available